Transepithelial Transport and Enzymatic Detoxification of Gluten in Gluten-Sensitive Rhesus Macaques

Background and Aims In a previous report, we characterized a condition of gluten sensitivity in juvenile rhesus macaques that is similar in many respects to the human condition of gluten sensitivity, celiac disease. This animal model of gluten sensitivity may therefore be useful toward studying both the pathogenesis and the treatment of celiac disease. Here, we perform two pilot experiments to demonstrate the potential utility of this model for studying intestinal permeability toward an immunotoxic gluten peptide and pharmacological detoxification of gluten in vivo by an oral enzyme drug candidate. Methods Intestinal permeability was investigated in age-matched gluten-sensitive and control macaques by using mass spectrometry to detect and quantify an orally dosed, isotope labeled 33-mer gluten peptide delivered across the intestinal epithelium to the plasma. The protective effect of a therapeutically promising oral protease, EP-B2, was evaluated in a gluten-sensitive macaque by administering a daily gluten challenge with or without EP-B2 supplementation. ELISA-based antibody assays and blinded clinical evaluations of this macaque and of an age-matched control were conducted to assess responses to gluten. Results Labeled 33-mer peptide was detected in the plasma of a gluten-sensitive macaque, both in remission and during active disease, but not in the plasma of healthy controls. Administration of EP-B2, but not vehicle, prevented clinical relapse in response to a dietary gluten challenge. Unexpectedly, a marked increase in anti-gliadin (IgG and IgA) and anti-transglutaminase (IgG) antibodies was observed during the EP-B2 treatment phase. Conclusions Gluten-sensitive rhesus macaques may be an attractive resource for investigating important aspects of celiac disease, including enhanced intestinal permeability and pharmacology of oral enzyme drug candidates. Orally dosed EP-B2 exerts a protective effect against ingested gluten. Limited data suggest that enhanced permeability of short gluten peptides generated by gastrically active glutenases may trigger an elevated antibody response, but that these antibodies are not necessarily causative of clinical illness.

[1]  Lu Shan,et al.  Structural Basis for Gluten Intolerance in Celiac Sprue , 2002, Science.

[2]  R. Jandacek,et al.  A Non-Human Primate Model for Gluten Sensitivity , 2008, PloS one.

[3]  L. Sollid.  Coeliac disease: dissecting a complex inflammatory disorder , 2002, Nature Reviews Immunology.

[4]  L. Greco,et al.  Compliance of adolescents with coeliac disease with a gluten free diet. , 1991, Gut.

[5]  C. Khosla,et al.  Design, synthesis, and evaluation of gluten peptide analogs as selective inhibitors of human tissue transglutaminase. , 2003, Chemistry & biology.

[6]  I. Bjarnason,et al.  Assessing the site of increased intestinal permeability in coeliac and inflammatory bowel disease. , 1996, Gut.

[7]  E. Bergseng,et al.  Structural basis for HLA-DQ2-mediated presentation of gluten epitopes in celiac disease , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[8]  L. Fugger,et al.  HLA binding and T cell recognition of a tissue transglutaminase‐modified gliadin epitope , 1999, European journal of immunology.

[9]  F. Koning,et al.  Enzymatic gluten detoxification: the proof of the pudding is in the eating! , 2006, Trends in biotechnology.

[10]  M. Cirillo,et al.  Long-Term Follow-Up of Celiac Adults on Gluten-Free Diet: Prevalence and Correlates of Intestinal Damage , 2002, Digestion.

[11]  F. Paparo,et al.  Anti-tissue transglutaminase antibodies from coeliac patients inhibit transglutaminase activity both in vitro and in situ , 2002, Gut.

[12]  I. Korponay-Szabó,et al.  Missing endomysial and reticulin binding of coeliac antibodies in transglutaminase 2 knockout tissues , 2003, Gut.

[13]  J. Kamer,et al.  Coeliac Disease The Presence in Wheat of a Factor Having a Deleterious Effect in Cases of Coeliac Disease , 1953, Acta paediatrica.

[14]  A. Levi,et al.  Intestinal permeability to 51Cr-EDTA in rats with experimentally induced enteropathy. , 1984, Gut.

[15]  H. Cornell,et al.  Enzyme therapy for management of coeliac disease , 2005, Scandinavian journal of gastroenterology.

[16]  Andrew G. Spencer,et al.  Combination enzyme therapy for gastric digestion of dietary gluten in patients with celiac sprue. , 2007, Gastroenterology.

[17]  L. Sollid,et al.  Identification and analysis of multivalent proteolytically resistant peptides from gluten: implications for celiac sprue. , 2005, Journal of proteome research.

[18]  H. Vora,et al.  Effect of Barley Endoprotease EP-B2 on Gluten Digestion in the Intact Rat , 2006, Journal of Pharmacology and Experimental Therapeutics.

[19]  L. Shan,et al.  Intestinal digestive resistance of immunodominant gliadin peptides. , 2002, American journal of physiology. Gastrointestinal and liver physiology.

[20]  N. Cerf-Bensussan,et al.  Oral proteases: a new approach to managing coeliac disease , 2006, Gut.

[21]  D. Kasarda,et al.  Innate and adaptive immunity: the Yin and Yang of celiac disease , 2005, Immunological reviews.

[22]  L. Sollid,et al.  Heterologous expression, purification, refolding, and structural-functional characterization of EP-B2, a self-activating barley cysteine endoprotease. , 2006, Chemistry & biology.

[23]  Peter P. Lee,et al.  Rational design of combination enzyme therapy for celiac sprue. , 2006, Chemistry & biology.

[24]  J. Murray,et al.  Gluten-free diet: the medical and nutrition management of celiac disease. , 2006, Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition.

[25]  M. Pietzak.  Follow-up of patients with celiac disease: achieving compliance with treatment. , 2005, Gastroenterology.

[26]  E. Thorsby,et al.  Dermatitis herpetiformis and celiac disease are both primarily associated with the HLA-DQ (α1*0501, (β1*02) or the HLA-DQ (α1*03, (β1*0302) heterodimers , 1997 .

[27]  E. Thorsby,et al.  Evidence for a primary association of celiac disease to a particular HLA-DQ alpha/beta heterodimer , 1989, The Journal of experimental medicine.

[28]  A. Price,et al.  Intestinal permeability in patients with coeliac disease and dermatitis herpetiformis. , 1985, Gut.

[29]  G. Corazza,et al.  Coeliac disease , 2005, Journal of Clinical Pathology.

[30]  E. Thorsby,et al.  Dermatitis herpetiformis and celiac disease are both primarily associated with the HLA-DQ (alpha 1*0501, beta 1*02) or the HLA-DQ (alpha 1*03, beta 1*0302) heterodimers. , 1997, Tissue antigens.

[31]  L. Sollid,et al.  Gliadin T Cell Epitope Selection by Tissue Transglutaminase in Celiac Disease , 2002, The Journal of Biological Chemistry.

[32]  J. Schulzke,et al.  Epithelial Tight Junction Structure in the Jejunum of Children with Acute and Treated Celiac Sprue , 1998, Pediatric Research.

[33]  E. Bergseng,et al.  Antigen Presentation to Celiac Lesion-Derived T Cells of a 33-Mer Gliadin Peptide Naturally Formed by Gastrointestinal Digestion1 , 2004, The Journal of Immunology.

[34]  J. Drijfhout,et al.  Specificity of Tissue Transglutaminase Explains Cereal Toxicity in Celiac Disease , 2002, The Journal of experimental medicine.

[35]  L. Sollid,et al.  Equilibrium and kinetic analysis of the unusual binding behavior of a highly immunogenic gluten peptide to HLA-DQ2. , 2005, Biochemistry.

[36]  I. Korponay-Szabó,et al.  In vivo targeting of intestinal and extraintestinal transglutaminase 2 by coeliac autoantibodies , 2004, Gut.

[37]  C. Khosla,et al.  A scaleable manufacturing process for pro‐EP‐B2, a cysteine protease from barley indicated for celiac sprue , 2007, Biotechnology and bioengineering.

[38]  W. Caspary,et al.  Celiac disease , 2006, Orphanet journal of rare diseases.

[39]  T. Peters,et al.  A PERSISTENT DEFECT IN INTESTINAL PERMEABILITY IN COELIAC DISEASE DEMONSTRATED BY A 51Cr-LABELLED EDTA ABSORPTION TEST , 1983, The Lancet.

[40]  W. W. Buchanan,et al.  LYSOSOMES IN DIVIDING CELLS. , 1965, Lancet.

[41]  A. Brunger,et al.  Transglutaminase 2 Undergoes a Large Conformational Change upon Activation , 2007, PLoS biology.

[42]  G. M. Gray,et al.  High selectivity of human tissue transglutaminase for immunoactive gliadin peptides: implications for celiac sprue. , 2002, Biochemistry.

[43]  T. Peters,et al.  In vitro determination of small intestinal permeability: demonstration of a persistent defect in patients with coeliac disease. , 1984, Gut.